Stockreport

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers [Yahoo! Finance]

Abpro Holdings, Inc  (ABP) 
NASDAQ:AMEX Investor Relations: abpro.com/contact
PDF ABP-102/CT-P72 represents Abpro's first IND submission for a phase 1 trial in a solid tumor indication, and is being co-developed by Abpro and Celltrion, Inc. BURLING [Read more]